NDUFB11 (Gene)

Organism:

Homo sapiens

Synonyms:CI-ESSS, ENTREZ:54539, ESSS, HGNC:20372, MC1DN30, MIM:300403, NADH:ubiquinone oxidoreductase subunit B11, NDUFB11, NM_001135998, NM_019056, NP17.3, NP_001129470, NP_061929, Np15, P17.3

Id:ENSG00000147123

Entrez:54539

Ensembl:ENSG00000147123

Description:NADH:ubiquinone oxidoreductase subunit B11

The protein encoded by this gene is a subunit of the multisubunit NADH:ubiquinone oxidoreductase (complex I). Mammalian complex I is located at the mitochondrial inner membrane. This protein has NADH dehydrogenase activity and oxidoreductase activity. It transfers electrons from NADH to ubiquinone. Mutations in the human gene are associated with linear skin defects with multiple congenital anomalies 3 and mitochondrial complex I deficiency. [provided by RefSeq, Dec 2016]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View NDUFB11's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with NDUFB11.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using NDUFB11.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for NDUFB11.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with NDUFB11.

Results found

Linked to

	Label	Description
	GSE102505 5 V 0 TUNICAMYCIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 0 V 3 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 9 V 13 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 5 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE217552 fisetin 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 trametinib NF1 9 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146612 2 V 0 AMIODARONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE133683 1 V 5 DOXORUBICIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS

GSE102505 5 V 0 TUNICAMYCIN HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 0 V 3 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 9 V 13 TRAMETINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE228106 3 V 5 PACLITAXEL HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE217552 fisetin 3 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 trametinib NF1 9 v 12 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE146612 2 V 0 AMIODARONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE133683 1 V 5 DOXORUBICIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.